<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00993681</url>
  </required_header>
  <id_info>
    <org_study_id>ELT301</org_study_id>
    <secondary_id>EudraCT Number: 2008-008726-75</secondary_id>
    <nct_id>NCT00993681</nct_id>
  </id_info>
  <brief_title>Travelers' Diarrhea (TD) Vaccine Pivotal Efficacy Study</brief_title>
  <official_title>A Phase Three, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers' Diarrhea Vaccine System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intercell USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intercell USA, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of the Travelers' Diarrhea Vaccine
      System to actively immunize against Enterotoxigenic Escherichia coli disease in a field
      setting.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of cases with vaccine preventable outcome</measure>
    <time_frame>Day 17 (17 days after arrival in destination country)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of moderate/severe diarrhea</measure>
    <time_frame>Day 17 (17 days after arrival in destination country)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total unformed stool frequency from diarrheal episodes</measure>
    <time_frame>Day 17 (17 days after arrival in destination country)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total duration of diarrheal episodes</measure>
    <time_frame>Day 17 (17 days after arrival in destination country)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2036</enrollment>
  <condition>Travelers' Diarrhea</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>900 subjects will receive a two vaccination regimen with an LT patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>900 subjects will receive a two vaccination regimen with a placebo patch</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TD Vaccine System</intervention_name>
    <description>heat labile enterotoxin of E. coli (LT)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TD Vaccine System</intervention_name>
    <description>placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-64 years of age at date of first vaccination

          -  Good health as determined by medical history and physical inspection

          -  Females of child-bearing potential must have a negative pregnancy test prior to first
             vaccination in teh Country of Origin; females of child-bearing potential must agree
             not to become pregnant throughout the duration of the study

          -  Subjects must have planned travel to an area within 3 hours traveling distance of
             Mexico City, Cuernavaca, Guadalajara, Oaxaca, or San Miguel de Allende, Mexico or
             Antigua, Quezaltenango, Guatemala City, or Solola, Guatemala for a minimum duration of
             stay 7 days (no maximum stay is specified for inclusion).

          -  Subject must be able to communicate in English

        Exclusion Criteria:

          -  Abnormalities as determined by the Investigator/clinician during physical inspection

          -  Participated in research involving investigational product within 30 days before
             planned date of first vaccination

          -  Ever received LT, ETEC, or cholera vaccine

          -  History of diarrhea while traveling to a developing country within the last year

          -  Women who are pregnant or breastfeeding

          -  Clinically significant underlying enteric, pulmonary, cardiac, liver or renal disease

          -  History of Irritable Bowel Syndrome

          -  Seizure disorder within the last year

          -  Current use of immunosuppressive therapy (excluding inhaled steroids) or current
             immunodeficiency

          -  Known or suspected alcohol abuse or illicit drug use within the last year

          -  Medical history of HIV, HBV, or HCV

          -  An employee of a study site

          -  Known allergies to any component of the vaccine, including adhesives

          -  Planned use of antibiotics with known activity against gram negative facultative
             anaerobes

          -  Planned use of antacids, antidiarrheals, loperamide, bismuth subsalicylate,
             diphenoxylate or similar during the surveillance phase of the study

          -  An employee of Intercell (global) or an immediate family member
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert L Dupont, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Infectious Diseases, The University of Texas Health Sciences Center at Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Berliner Centrum Reise &amp; Tropenmedizin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20359</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilians-Universitat Abt. for Infektions and Tropenmedizin</name>
      <address>
        <city>Munchen</city>
        <zip>80802</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik for Gastroenterologie &amp; Infektiologie</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorio Privado</name>
      <address>
        <city>Quetzaltenango</city>
        <state>Quezaltenango CP</state>
        <zip>09001</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trek Study Antigua</name>
      <address>
        <city>Antigua</city>
        <zip>03001</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isthmian Medical Research Guatemala S.A.</name>
      <address>
        <city>Guatemala</city>
        <zip>01015</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SAMI-SSAPFORFAM Consultorio Privado</name>
      <address>
        <city>Solola</city>
        <zip>07001</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roberto Maxwell's Office</name>
      <address>
        <city>San Miguel de Allende</city>
        <state>Guanajuato</state>
        <zip>37700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorio Privado Torre Medica San Javier</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44670</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mexican Institute of Clinical Research (IMIC)</name>
      <address>
        <city>Mexico City</city>
        <state>Mexico D.F.</state>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine Trek Study Cuernavaca</name>
      <address>
        <city>Cuernavaca</city>
        <state>Morelos</state>
        <zip>62250</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Reforma</name>
      <address>
        <city>Oaxaca de Juarez</city>
        <state>Oaxaca</state>
        <zip>68000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Thames Valley Clinical Research Center</name>
      <address>
        <city>Reading</city>
        <state>Berkshire</state>
        <zip>RG2 0TG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Midlands Clinical Research Center</name>
      <address>
        <city>Edgbaston</city>
        <state>Birmingham</state>
        <zip>B15 2SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Lancashire Clinical Research Center</name>
      <address>
        <city>Chorley</city>
        <state>Lancashire</state>
        <zip>PR7 7NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's Drug Research Unit</name>
      <address>
        <city>London Bridge</city>
        <state>London</state>
        <zip>SE1 1YR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bio-Kinetic Europe Ltd</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT2 7 BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Scotland Clinical Research Center</name>
      <address>
        <city>Glasgow</city>
        <state>Scottland</state>
        <zip>G81 2DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Tropical Diseases</name>
      <address>
        <city>London</city>
        <zip>WC1E 6JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Mexico</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2009</study_first_submitted>
  <study_first_submitted_qc>October 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2009</study_first_posted>
  <last_update_submitted>March 13, 2012</last_update_submitted>
  <last_update_submitted_qc>March 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention of Travelers' Diarrhea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
    <mesh_term>Dysentery</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

